
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
New York-Japanese patients have access to the only treatment for some forms of wet age-related macular degeneration (AMD) with the launch of verteporfin (Visudyne, QLT PhotoTherapeutics/Novartis Ophthalmics) in Japan.




